Morgan Stanley downgraded Afya from Equal-Weight to Underweight and set a new price target of $16.00
Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 2/24/2026 | $17.00 | Buy → Neutral | BofA Securities |
| 2/13/2026 | $16.00 | Equal-Weight → Underweight | Morgan Stanley |
| 1/16/2026 | $16.00 | Buy → Neutral | UBS |
| 1/7/2026 | $22.00 | Overweight → Neutral | Analyst |
| 9/8/2025 | $24.50 | Neutral → Overweight | Analyst |
| 9/8/2025 | $19.00 | Neutral → Buy | UBS |
| 8/6/2025 | $17.50 | Underweight → Overweight | Morgan Stanley |
| 7/29/2025 | $14.00 | Sell → Neutral | Citigroup |
6-K - Afya Ltd (0001771007) (Filer)
6-K - Afya Ltd (0001771007) (Filer)
6-K - Afya Ltd (0001771007) (Filer)
BofA Securities downgraded Afya from Buy to Neutral and set a new price target of $17.00
Morgan Stanley downgraded Afya from Equal-Weight to Underweight and set a new price target of $16.00
UBS downgraded Afya from Buy to Neutral and set a new price target of $16.00
Another Year of Strong Performance Guidance Achievement Afya Limited (NASDAQ:AFYA, B3: A2FY34)) ("Afya" or the "Company"), the leading medical education group and medical practice solutions provider in Brazil, reported today its financial and operating results for the fourth quarter and full-year period ended December 31, 2025. Financial results are expressed in Brazilian Reais and are presented in accordance with International Financial Reporting Standards (IFRS). Fourth Quarter 2025 Highlights 4Q25 Revenue increased 7.5% YoY to R$913.0 million. Revenue excluding acquisitions increased 7.3%, reaching R$910.8 million. 4Q25 Adjusted EBITDA increased 6.1% YoY, reaching R$388.5 milli
Afya Limited (NASDAQ:AFYA, B3: A2FY34)) ("Afya" or the "Company"), the leading medical education group and medical practice solutions provider in Brazil, announced that its board of directors (the "Board") approved its second distribution of a cash dividend. On March 12, 2026, the Company's Board of Directors approved dividend distribution in the amount of R$307.4 million, representing 40% of the Company's consolidated net income for the year ended December 31, 2025 and a dividend per share of R$3.446838, payable in U.S. dollars on April 6, 2026, to the shareholders on record as of the close of business on March 25, 2025. The payment will be made at the exchange rate (PTAX) to be publishe
Afya Limited (NASDAQ:AFYA, B3: A2FY34)) ("Afya" or the "Company"), the leading medical education group and provider of medical practice solutions in Brazil, today announced that the Secretary of Regulation and Supervision of Higher Education of the Ministry of Education ("MEC") has authorized an increase of 63 medical seats for ITPAC – Instituto Tocantinense Presidente Antonio Carlos Porto S.A. ("Afya Abaetetuba"), located in the city of Abaetetuba, in the state of Pará. With this authorization, Afya's Abaetetuba campus will offer a total of 113 medical seats. As Afya Cametá—an approved but, non-operating medical school —and Afya Abaetetuba are located within the same health region, Afya
Another Year of Strong Performance Guidance Achievement Afya Limited (NASDAQ:AFYA, B3: A2FY34)) ("Afya" or the "Company"), the leading medical education group and medical practice solutions provider in Brazil, reported today its financial and operating results for the fourth quarter and full-year period ended December 31, 2025. Financial results are expressed in Brazilian Reais and are presented in accordance with International Financial Reporting Standards (IFRS). Fourth Quarter 2025 Highlights 4Q25 Revenue increased 7.5% YoY to R$913.0 million. Revenue excluding acquisitions increased 7.3%, reaching R$910.8 million. 4Q25 Adjusted EBITDA increased 6.1% YoY, reaching R$388.5 milli
Afya Limited (NASDAQ:AFYA, B3: A2FY34)) ("Afya" or the "Company"), the leading medical education group and medical practice solutions provider in Brazil, announced that its board of directors (the "Board") approved its second distribution of a cash dividend. On March 12, 2026, the Company's Board of Directors approved dividend distribution in the amount of R$307.4 million, representing 40% of the Company's consolidated net income for the year ended December 31, 2025 and a dividend per share of R$3.446838, payable in U.S. dollars on April 6, 2026, to the shareholders on record as of the close of business on March 25, 2025. The payment will be made at the exchange rate (PTAX) to be publishe
Impressive Adjusted EBITDA Margin Expansion and Cash Generation Full Year 2025 Guidance Reaffirmed Afya Limited (NASDAQ:AFYA, B3: A2FY34)) ("Afya" or the "Company"), the leading medical education group and medical practice solutions provider in Brazil, reported today its financial and operating results for the three and nine-month period, which ended September 30, 2025 (third quarter 2025). Financial results are expressed in Brazilian Reais and are presented in accordance with International Financial Reporting Standards (IFRS). Third Quarter 2025 Highlights 3Q25 Revenue increased 10.4% YoY to R$928.5 million. Revenue excluding acquisitions increased 10.1%, reaching R$926.2 million.
Afya Limited, or "Afya" (NASDAQ:AFYA) announced today that the resolutions set out in its Notice of Annual General Meeting dated June 9, 2025 was duly passed at its Annual General Meeting held today: (1) the approval and ratification of Afya's financial statements as of and for the fiscal year ended December 31, 2024; (2) the re-appointment of João Paulo Seibel de Faria as an independent director of the Company with immediate effect to hold office for a two year term; (3) the re-appointment of Vanessa Claro Lopes as an independent director of the Company with immediate effect to hold office for a two year term; (4) the re-appointment of Miguel Filisbino Pereira de Paula as an independent di
NOVA LIMA, Brazil and MINAS GERAIS, Brazil, Jan. 15, 2021 (GLOBE NEWSWIRE) -- Afya Limited, or Afya (Nasdaq: AFYA), today announces that its clinical decision software, WhiteBook, an app created by PEBMED, was ranked as one of the 10 Top Apps in Brazil by consumer spend in 2020 for the fifth year in a row. App Annie conducted the study, a website specialized in app analytics and app market data that combined data from iOS and Google Play that evaluates more than 8 million mobile app per year. In the top ten WhiteBook was among great apps such as Tinder, YouTube, Netflix, TikTok and others. Whitebook is a mobile and web application software that helps doctors and medical students to make
SC 13G/A - Afya Ltd (0001771007) (Subject)
SC 13G/A - Afya Ltd (0001771007) (Subject)
SC 13G/A - Afya Ltd (0001771007) (Subject)